Filtered By:
Management: Insurance
Vaccination: Meningitis Vaccine
This page shows you your search results in order of date.
Order by Relevance | Date
Total 109 results found since Jan 2013.
Vaccination Coverage Among Adolescents Aged 13-17 Years - National Immunization Survey-Teen, United States, 2022
MMWR Morb Mortal Wkly Rep. 2023 Aug 25;72(34):912-919. doi: 10.15585/mmwr.mm7234a3.ABSTRACTThree vaccines are routinely recommended for adolescents to prevent pertussis, meningococcal disease, and cancers caused by human papillomavirus (HPV). CDC analyzed data from the 2022 National Immunization Survey-Teen for 16,043 adolescents aged 13-17 years to assess vaccination coverage. Birth cohort analyses were conducted to assess trends in vaccination coverage by age 13 years (i.e., before the 13th birthday) and by age 14 years (i.e., before the 14th birthday) among adolescents who were due for routine vaccination before and dur...
Source: MMWR Morb Mortal Wkl... - August 24, 2023 Category: Epidemiology Authors: Cassandra Pingali David Yankey Laurie D Elam-Evans Lauri E Markowitz Madeleine R Valier Benjamin Fredua Samuel J Crowe Carla L DeSisto Shannon Stokley James A Singleton Source Type: research
Pneumonia hospitalization after introduction of pneumococcal conjugate vaccine in Japan: Descriptive study using a nationwide claims database
CONCLUSION: Our study estimated 4-6 pneumonia hospitalizations per 1000 pediatric population in Japan, with a 34 % decrease after the introduction of PCV. This study examined the nationwide effectiveness of PCV, further studies are needed in all age groups.PMID:37286407 | DOI:10.1016/j.vaccine.2023.05.065
Source: Vaccine - June 7, 2023 Category: Allergy & Immunology Authors: Takanori Yanai Satomi Yoshida Masato Takeuchi Koji Kawakami Source Type: research
Pneumococcal vaccination coverage at the initiation of chronic dialysis, and its association with mortality during the first year
CONCLUSIONS: Pneumococcal immunization with PCV13 followed by PPSV23, or with PCV13 alone, but not with PPSV23 alone, is independently associated with decreased one year-mortality in patients who start dialysis.PMID:37179164 | DOI:10.1016/j.vaccine.2023.05.003
Source: Vaccine - May 13, 2023 Category: Allergy & Immunology Authors: Élodie Pierre Ad élaïde Pladys Sahar Bayat-Makoei Pierre Tattevin C écile Vigneau Source Type: research
Impacts of Catch-Up Immunization program with the 13-Valent pneumococcal Conjugate vaccine in Taiwan: Focus on age-stratified differences and high-risk population (2001-2015)
CONCLUSIONS: Our study suggests that the introduction of this catch-up program with PCV13 was associated with significant declines in the incidence of pneumococcal pneumonia and all-cause pneumonia in vaccinated children, and indirect protection from the program was also found in unvaccinated children.PMID:36127209 | DOI:10.1016/j.vaccine.2022.09.002
Source: Vaccine - September 20, 2022 Category: Allergy & Immunology Authors: Shih-Tsung Huang Yhu-Chering Huang Edward Kuo Ya-Min Yang Fei-Yuan Hsiao Source Type: research
Development and application of a Japanese vaccine database for comparative assessments in the post-authorization phase: The Vaccine Effectiveness, Networking, and Universal Safety (VENUS) study
CONCLUSIONS: The VENUS Study is Japan's first healthcare data platform that enables comparative assessments of vaccinated and unvaccinated persons in large samples covering all age groups. Efforts are underway to increase the number of participating municipalities and to generate evidence on vaccine effectiveness and safety.PMID:36096969 | DOI:10.1016/j.vaccine.2022.08.069
Source: Vaccine - September 12, 2022 Category: Allergy & Immunology Authors: Chieko Ishiguro Wataru Mimura Fumiko Murata Haruhisa Fukuda Source Type: research
Pneumococcal and influenza vaccination coverage among at-risk adults: A 5-year French national observational study
CONCLUSION: Pneumococcal and influenza vaccination coverage of adults at risk of pneumococcal disease fell well below public health expectations. Invitations for pneumococcal vaccination should be sent by the NHI to high-risk patients. Patient management protocols should include pneumococcal vaccination. Patients with multiple comorbidities are a high-priority population given the large potential health gains offered by pneumococcal vaccination. Commitment of both scientific societies and health authorities is urgently needed to increase vaccination coverage in at-risk populations.PMID:35811205 | DOI:10.1016/j.vaccine.2022.06.071
Source: Vaccine - July 10, 2022 Category: Allergy & Immunology Authors: Benjamin Wyplosz J érôme Fernandes Ariane Sultan Nicolas Roche Fran çois Roubille Paul Loubet Bertrand Foug ère Bruno Moulin Didier Duhot Alexandre Vainchtock Fanny Raguideau Joannie Lortet-Tieulent Emmanuelle Blanc Jennifer Mo ïsi Gwena ël Goussiau Source Type: research
Impact of pneumococcal conjugate vaccination on hospitalized childhood pneumonia in Taiwan
CONCLUSIONS: Pneumococcal parapneumonic diseases and the disease burden of lobar/pneumococcal pneumonia and lower respiratory tract infections declined after the national PCV13 vaccination program.IMPACT: The impact study of the PCV13 immunization program on childhood pneumonia in Asian countries remained limited. The unique PCV13 immunization program in Taiwan, catch-up before primary infantile series, reduced severe childhood pneumococcal pneumonia at 5 years post PCV13. The intensive and invasive medical needs and fatality of all-cause pneumonia decreased significantly in children of all ages. We observed an increase in...
Source: Pediatric Research - December 23, 2021 Category: Pediatrics Authors: Jian-Te Lee Jou-Wei Lin Ho-Min Chen Chen-Yu Wang Chun-Yi Lu Luan-Yin Chang Li-Min Huang Source Type: research
